Our group has recently shown that erythrocytes obtained from NAFLD patients exhibited increased membrane cholesterol, sphingosine, bound chemokine MCP1 [96], reduced levels of sphingomyelin [97], and CD47 [96], while also increasing the release of MCP1 [98] and the sustained release of sphingosine-1 phosphate and lysophosphatidic acid [98]. The gene discussed is CCL2; the disease is metabolic dysfunction-associated steatotic liver disease.